Q1 2026 Gossamer Bio Inc Earnings Call Transcript
Key Points
- Gossamer Bio Inc (GOSS) reported a clinically meaningful improvement in the Phase III Procera study of seralutinib, showing a placebo-adjusted improvement of 13.3 meters in 6-minute walk distance.
- The company has engaged with the FDA, advancing from a Type C meeting to a Type B pre-NDA meeting, indicating progress in regulatory discussions.
- The CT FRI substudy showed multi-compartment structural reverse remodeling, providing anatomical support for seralutinib's efficacy.
- Gossamer Bio Inc (GOSS) has taken decisive financial actions, including a significant reduction in force and operating expenses, to preserve financial stability.
- The company successfully negotiated a convertible note exchange, reducing outstanding convertible debt from $200 million to under $72 million and extending debt maturity to 2030.
- The Phase III Procera study did not meet the prespecified 0.025 alpha threshold for statistical significance, creating some uncertainty around the results.
- A significant reduction in force affected approximately half of the company, indicating potential operational challenges.
- The company faces risks and uncertainties related to regulatory approval and commercialization of seralutinib.
- The upcoming 2027 maturity of convertible senior notes required proactive capital structure adjustments, highlighting financial pressures.
- The CT FRI substudy results are exploratory and the p-values are nominal and unadjusted for multiplicity, which may limit their impact on regulatory decisions.
Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Gossamer Bio Q1 2026 Earnings Call. (Operator Instructions).
It is now my pleasure to turn the call over to Bryan Giraudo, Chief Operating Officer and Chief Financial Officer. Please go ahead.
Good morning, and thank you for joining us. Before we begin, I'd like to remind listeners that today's discussion includes forward-looking statements including statements regarding our regulatory plans, potential NDA submission and approval timing commercialization, expectations, cash runway, capital structure and the potential to benefit in future developments of seralutinib.
These statements are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings and today's press release for discussions of these risks. We undertake no obligation to update these forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
